Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT03241810. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer (Merrimack Pharmaceuticals Inc.)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a multi-center, randomized, double-blind, placebo-controlled, Phase 2 study in postmenopausal women with heregulin positive, hormone receptor positive, HER2 negative metastatic, unresectable breast cancer.
Study identification
- NCT ID
- NCT03241810
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 15, 2017 (Actual)
- Primary completion
- Nov 30, 2018 (Actual)
- Completion
- Nov 30, 2018 (Actual)
- Last update posted
- Sep 2, 2020
2017 – 2018
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer and Research Centers- Chandler | Chandler | Arizona | 85224 | — |
| Highland Oncology Group | Fayetteville | Arkansas | 72703 | — |
| Beverly Hills Cancer Center | Beverly Hills | California | 90404-2131 | — |
| Stanford University | Palo Alto | California | 94304 | — |
| Saint Helena Hospital | St. Helena | California | 94574 | — |
| Stamford Hospital | Stamford | Connecticut | 06902-3628 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| UF Health Cancer Center at Orlando Health | Orlando | Florida | 32806 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Columbus Regional Research Institute | Columbus | Georgia | 31904 | — |
| Cancer Care Specialists of Central Illinois | Decatur | Illinois | 62526 | — |
| James M Stockman Cancer Institute | Frederick | Maryland | 21701 | — |
| Holy Cross Hospital Health Center | Silver Spring | Maryland | 20902 | — |
| Lahey Clinical Medical Center | Burlington | Massachusetts | 01805 | — |
| University of Mississippi | Jackson | Mississippi | 39216 | — |
| Mercy Hospital Springfield | Springfield | Missouri | 65804 | — |
| Saint Francis Cancer Treatment Center | Grand Island | Nebraska | 68803 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | — |
| Oncology Specialists of Charlotte | Charlotte | North Carolina | 28207 | — |
| UPMC Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| University of Utah Health Care - Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03241810, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2020 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03241810 live on ClinicalTrials.gov.